Novo, Nordisk

Novo Nordisk Lifts Full-Year Guidance as Sickle Cell, Haemophilia and Obesity Pipeline Advances

Published on 11/16/2026 at 09:11 | Editorial boerse-global.de
Novo Nordisk raised its 2026 outlook, filed Etavopivat for sickle cell disease in the US and EU, won EU approval for a haemophilia A drug and presented CagriSema data.
Novo, Nordisk, Lifts, Full-Year, Guidance, Sickle, Cell, Haemophilia, Obesity, Pipeline Illustration mit AI erstellt.

Novo Nordisk has spent a busy stretch firing on several fronts at once, and investors have taken notice: the stock closed Friday up 2.7%. The Danish drugmaker raised its full-year outlook, filed for approval of a sickle cell therapy on two continents, secured an EU green light for a haemophilia treatment and unveiled fresh analyses of its experimental obesity candidate — all while US regulators moved to add a new warning to its blockbuster GLP-1 medicines.

Guidance Raised After Strong Third Quarter

The upward revision came on 4 November, when Novo Nordisk reported third-quarter 2026 results and lifted its forecasts for the year. Management now expects adjusted revenue growth and adjusted operating profit growth each in a range of minus 2% to plus 2% at constant exchange rates.

Adjusted quarterly revenue came in at DKK 79.2 billion, a rise of 4% at constant currencies. Adjusted operating profit reached DKK 31.72 billion, up 27% — a figure that landed above market expectations, according to Reuters.

Two Filings for Etavopivat

Friday also brought regulatory paperwork for Etavopivat, an as-yet-unapproved candidate for sickle cell disease. Novo Nordisk submitted a new drug application to the US Food and Drug Administration and a marketing authorisation application to the European Medicines Agency. The proposed regimen is a once-daily oral therapy for patients aged twelve and older.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

EU Approval for Haemophilia A Drug

On the same day, the European Commission granted approval to a Novo Nordisk treatment for haemophilia A. As Reuters reported, the clearance covers the prevention or reduction of bleeding episodes in both adults and children.

FDA Wants Eye-Risk Warnings on GLP-1 Labels

The GLP-1 franchise, meanwhile, faces a labelling change. According to Reuters, the FDA asked manufacturers last Monday to add warnings about a possible increased risk of non-arteritic anterior ischaemic optic neuropathy, or NAION. At Novo Nordisk, the requirement affects Ozempic and Wegovy. The company said it remains convinced of the benefit-risk profile of its medicines.

CagriSema Post-Hoc Data Presented at ObesityWeek

At ObesityWeek, Novo Nordisk presented further post-hoc analyses of the Phase 3 REDEFINE 1 trial of CagriSema, its obesity candidate still in development. Among participants treated with the drug, 73.1% showed a meaningful improvement in physical function, compared with 49.1% on placebo. A separate analysis found that 67.8% of CagriSema-treated participants were early responders, a group for which the company reported pronounced average weight loss through the treatment week examined. Novo Nordisk explicitly labelled both sets of findings as retrospective analyses of the same Phase 3 study.

$200 Million for the World Diabetes Foundation

Midweek, Novo Nordisk committed USD 200 million to the World Diabetes Foundation, Reuters reported. The pledge runs from 2027 to 2036 and is intended to support diabetes prevention and care in low- and middle-income countries.

Ad

Novo Nordisk Stock: New Analysis - 16 November

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

Disclaimer...
en | DK0062498333 | NOVO | boerse | 70519965 |